NANOBIOTIX SA - ADR (NBTX) Stock Fundamental Analysis

NASDAQ:NBTX • US63009J1079

25.34 USD
+0.85 (+3.47%)
Last: Feb 13, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, NBTX scores 1 out of 10 in our fundamental rating. NBTX was compared to 522 industry peers in the Biotechnology industry. Both the profitability and financial health of NBTX have multiple concerns. NBTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NBTX had negative earnings in the past year.
  • In the past year NBTX has reported a negative cash flow from operations.
  • NBTX had negative earnings in each of the past 5 years.
  • NBTX had a negative operating cash flow in each of the past 5 years.
NBTX Yearly Net Income VS EBIT VS OCF VS FCFNBTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • NBTX has a Return On Assets of -114.32%. This is in the lower half of the industry: NBTX underperforms 78.59% of its industry peers.
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBTX Yearly ROA, ROE, ROICNBTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NBTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBTX Yearly Profit, Operating, Gross MarginsNBTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • NBTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NBTX has been increased compared to 1 year ago.
  • The number of shares outstanding for NBTX has been increased compared to 5 years ago.
  • Compared to 1 year ago, NBTX has a worse debt to assets ratio.
NBTX Yearly Shares OutstandingNBTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NBTX Yearly Total Debt VS Total AssetsNBTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -12.14, we must say that NBTX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of NBTX (-12.14) is worse than 76.10% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.14
ROIC/WACCN/A
WACC7.93%
NBTX Yearly LT Debt VS Equity VS FCFNBTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

  • NBTX has a Current Ratio of 0.63. This is a bad value and indicates that NBTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of NBTX (0.63) is worse than 88.91% of its industry peers.
  • NBTX has a Quick Ratio of 0.63. This is a bad value and indicates that NBTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NBTX has a Quick ratio of 0.63. This is amonst the worse of the industry: NBTX underperforms 88.53% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
NBTX Yearly Current Assets VS Current LiabilitesNBTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • NBTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -47.30%.
  • Looking at the last year, NBTX shows a very negative growth in Revenue. The Revenue has decreased by -138.77% in the last year.
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.40% on average over the next years. This is quite good.
  • NBTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.60% yearly.
EPS Next Y46.17%
EPS Next 2Y18.23%
EPS Next 3Y22.28%
EPS Next 5Y13.4%
Revenue Next Year24.15%
Revenue Next 2Y74.49%
Revenue Next 3Y23.29%
Revenue Next 5Y19.6%

3.3 Evolution

NBTX Yearly Revenue VS EstimatesNBTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M 600M
NBTX Yearly EPS VS EstimatesNBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • NBTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBTX Price Earnings VS Forward Price EarningsNBTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBTX Per share dataNBTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NBTX's earnings are expected to grow with 22.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.23%
EPS Next 3Y22.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NBTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NANOBIOTIX SA - ADR

NASDAQ:NBTX (2/13/2026, 8:00:01 PM)

25.34

+0.85 (+3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)03-31
Inst Owners28.98%
Inst Owner Change0.17%
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap1.23B
Revenue(TTM)-14.04M
Net Income(TTM)-51.64M
Analysts85
Price Target28.03 (10.62%)
Short Float %0.07%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.4%
PT rev (3m)23.8%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-21.65%
EPS NY rev (3m)-20.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS-0.34
BVpS-1.69
TBVpS-1.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.5%
Cap/Sales -3.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -12.14
F-Score2
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
EPS Next Y46.17%
EPS Next 2Y18.23%
EPS Next 3Y22.28%
EPS Next 5Y13.4%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%
Revenue Next Year24.15%
Revenue Next 2Y74.49%
Revenue Next 3Y23.29%
Revenue Next 5Y19.6%
EBIT growth 1Y-159.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.73%
EBIT Next 3Y34.05%
EBIT Next 5Y0.83%
FCF growth 1Y14.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.92%
OCF growth 3YN/A
OCF growth 5YN/A

NANOBIOTIX SA - ADR / NBTX FAQ

What is the ChartMill fundamental rating of NANOBIOTIX SA - ADR (NBTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NBTX.


Can you provide the valuation status for NANOBIOTIX SA - ADR?

ChartMill assigns a valuation rating of 1 / 10 to NANOBIOTIX SA - ADR (NBTX). This can be considered as Overvalued.


Can you provide the profitability details for NANOBIOTIX SA - ADR?

NANOBIOTIX SA - ADR (NBTX) has a profitability rating of 0 / 10.